ArticleJournal of ovarian research2026
Evaluating the PCOS risk algorithm (PriskA): a pilot study.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolycystic ovary syndrome (PCOS) is a heterogeneous disorder with reproductive, metabolic, and psychological features, often underdiagnosed due to diagnostic inaccuracies and inconsistent knowledge among providers. These gaps highlight the need for improved diagnostic approaches to identify patients at risk earlier. This pilot study aimed to evaluate the validity of the PCOS risk algorithm (PriskA), a digital tool designed to assess PCOS risk in symptomatic women.
resultsA total of 144 women were referred for standardized endocrine screening at the Erasmus Medical centre and were included in the study, after excluding six women with inconclusive diagnoses. Of the 95 women with PCOS, 91 (96%) received a high PriskA score. Among the 49 without PCOS, 35% received a low score, 53% a high score, and 12% a moderate score. ROC analysis (high versus low scores) showed a sensitivity of 0.97 and specificity of 0.40, which improved to 0.45 when Elecsys AMH ≥ 3.2 ng/mL replaced ultrasound for diagnosing polycystic ovarian morphology (PCOM). Refining the algorithm increased specificity to 0.77 (AMH for PCOM) and 0.67 (ultrasound for PCOM).
conclusionsIn this pilot study, PriskA proved to be a promising tool for assessing PCOS risk, particularly in primary care settings. It showed high sensitivity and minimal missed cases, making it especially useful where timely diagnosis is critical yet often challenging. By enabling earlier referrals, PriskA has the potential to reduce diagnostic delays, improve PCOS management, and help prevent associated comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.